EUVIMEDEUVIMED entdecken
Crossref

Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress

Ram Sharma, Yung-Hsiao Chiang, Hsien-Chung Chen, Hong-Yi Lin, Wen-Bin Yang, Kunal Nepali, Mei-Jung Lai, Kai-Yun Chen, Jing-Ping Liou, Tsung-I Hsu

Cancer Letters · 2024

DOI: 10.1016/j.canlet.2024.216666 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Ram Sharma und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Androstenes, Brain Neoplasms, Glioblastoma, Steroid 17-alpha-Hydroxylase. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is a highly aggressive and treatment-resistant brain tumor, necessitating novel therapeutic strategies. In this study, we present a mechanistic breakthrough by designing and evaluating a series of abiraterone-installed hydroxamic acids as potential dual inhibitors of CYP17A1 and HDAC6 for GBM treatment. We established the correlation of CYP17A1/HDAC6 overexpression with tumor recurrence and temozolomide resistance in GBM patients. Compound 12, a dual inhibitor, demonstrated significant anti-GBM activity in vitro, particularly against TMZ-resistant cell lines. Mechanistically, compound 12 induced apoptosis, suppressed recurrence-associated genes, induced oxidative stress and initiated DNA damage response. Furthermore, molecular modeling studies confirmed its potent inhibitory activity against CYP17A1 and HDAC6. In vivo studies revealed that compound 12 effectively suppressed tumor growth in xenograft and orthotopic mouse models without inducing significant adverse effects. These findings highlight the potential of dual CYP17A1 and HDAC6 inhibition as a promising strategy for overcoming treatment resistance in GBM and offer new hope for improved therapeutic outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AndrostenesBrain NeoplasmsGlioblastomaSteroid 17-alpha-HydroxylaseAnimalsHumansMiceAntineoplastic Agents, AlkylatingCell Line, TumorDNA DamageDrug Resistance, NeoplasmHistone Deacetylase 6Hydroxamic AcidsNeoplasm Recurrence, LocalOxidative StressTemozolomideXenograft Model Antitumor Assays

Stichwörter der Autor:innen

CYP17A1GlioblastomaHDAC6Temozolomide resistance

Substanzen

abirateroneAndrostenesAntineoplastic Agents, AlkylatingCYP17A1 protein, humanHDAC6 protein, humanHistone Deacetylase 6Hydroxamic AcidsSteroid 17-alpha-HydroxylaseTemozolomide

Autor:innen und Institutionen

  • School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
  • Department of Neurosurgery, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan; Ph.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University and…
  • Ph.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University and National Health Research Institutes, Taipei, Taiwan; Taipei Neuroscience Institute, Taipei Medical Universi…
  • Taipei Neuroscience Institute, Taipei Medical University, Taipei, Taiwan; Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • Ph.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University and National Health Research Institutes, Taipei, Taiwan; TMU Research Center of Neuroscience, Taipei Medical Un…
  • School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan; TMU Research Center for Drug Discovery, Taipei Medical University, Taipei, Taiwan; Ph.D. Program in Drug Discovery and Development Indu…

Förderung

  • National Science and Technology Council

Zitieren

APA

Sharma, R., Chiang, Y. H., Chen, H. C., Lin, H. Y., Yang, W. B., Nepali, K., Lai, M. J., Chen, K. Y., Liou, J. P., & Hsu, T. I. (2024). Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.216666

Vancouver

Sharma R, Chiang YH, Chen HC, Lin HY, Yang WB, Nepali K, et al. Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.216666

BibTeX
@article{Sharma2024,
  author = {Sharma, Ram and Chiang, Yung-Hsiao and Chen, Hsien-Chung and Lin, Hong-Yi and Yang, Wen-Bin and Nepali, Kunal and Lai, Mei-Jung and Chen, Kai-Yun and Liou, Jing-Ping and Hsu, Tsung-I},
  title = {Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress},
  journal = {Cancer Letters},
  year = {2024},
  doi = {10.1016/j.canlet.2024.216666}
}
Kostenlos starten →